持续按压联合非同步通气能否改善心肺复苏预后?基于人体与动物研究的Meta分析
该Meta分析检索PubMed、Web of Science、Embase、MEDLINE和Cochrane图书馆至2022年7月31日,纳入8项人体研究和12项动物研究,比较持续胸外按压联合非同步通气(CCC-CPR)与间断胸外按压联合同步通气(ICC-CPR)。人体研究中,两组在自主循环恢复(OR 1.07,95%CI 0.86-1.32,P=0.55)、出院生存(OR 1.04,95%CI 0.77-1.42,P=0.79)、1个月生存(OR 1.07,95%CI 0.84-1.36,P=0.57)和良好神经功能预后(OR 0.92,95%CI 0.84-1.01,P=0.09)方面均无显著差异。动物实验中,CCC-CPR组自主循环恢复(OR=1.81,95%CI 0.94-3.49,P=0.07)、4小时生存(OR 2.57,95%CI 1.16-5.72,P=0.02)和平均动脉压(MD 0.79,95%CI 0.04-1.53,P=0.04)较高,但自主循环恢复时间、动脉pH和动脉二氧化碳分压无显著差异。作者认为应将动物实验的积极结果转化至人体模型,并需在不同按压-通气策略的心肺复苏患者中确认更多生理机制。
要点
- 人体研究中,CCC-CPR与ICC-CPR相比,自主循环恢复无显著差异(OR 1.07,95%CI 0.86-1.32,P=0.55)。
- 人体研究中,出院生存(OR 1.04,95%CI 0.77-1.42,P=0.79)和1个月生存(OR 1.07,95%CI 0.84-1.36,P=0.57)均无显著差异。
- 人体研究中,良好神经功能预后无显著差异(OR 0.92,95%CI 0.84-1.01,P=0.09)。
- 动物实验中,CCC-CPR组4小时生存(OR 2.57,95%CI 1.16-5.72,P=0.02)和平均动脉压(MD 0.79,95%CI 0.04-1.53,P=0.04)较高,自主循环恢复OR=1.81(95%CI 0.94-3.49,P=0.07)。
- 作者认为应将动物实验的积极结果应用于人体模型,并需在不同按压-通气策略的心肺复苏患者中确认更多生理机制。
适用人群与场景
- 人体研究:心脏骤停患者,比较持续胸外按压联合非同步通气(CCC-CPR)与间断胸外按压联合同步通气(ICC-CPR)。
- 动物研究:动物心脏骤停模型,同样比较CCC-CPR与ICC-CPR。
研究设计与关键结果
- 研究类型:Meta分析,纳入8项人体研究和12项动物研究,检索PubMed、Web of Science、Embase、MEDLINE(Ovid/LWW)和Cochrane图书馆,检索时间从建库至2022年7月31日。
- 人体研究主要终点:CCC-CPR与ICC-CPR相比,自主循环恢复无显著差异(OR 1.07,95%CI 0.86-1.32,P=0.55)。
- 人体研究次要终点:出院生存无显著差异(OR 1.04,95%CI 0.77-1.42,P=0.79);1个月生存无显著差异(OR 1.07,95%CI 0.84-1.36,P=0.57);良好神经功能预后无显著差异(OR 0.92,95%CI 0.84-1.01,P=0.09)。
- 动物研究:CCC-CPR组自主循环恢复OR=1.81(95%CI 0.94-3.49,P=0.07);4小时生存OR 2.57(95%CI 1.16-5.72,P=0.02);平均动脉压MD 0.79(95%CI 0.04-1.53,P=0.04);自主循环恢复时间、动脉pH和动脉二氧化碳分压无显著差异。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入人体研究和动物研究;使用Jadad量表和Newcastle-Ottawa量表评估研究质量和偏倚风险。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,应将动物实验中的积极结果应用于人体模型,并需在不同按压-通气策略的心肺复苏患者中确认更多生理机制,以改善心脏骤停预后。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The cardiopulmonary resuscitation (CPR) compression to ventilation strategy remains controversial. We conducted a meta-analysis to compare the outcomes between continuous chest compressions CPR with asynchronous ventilation (CCC-CPR) and interrupted chest compressions CPR with synchronous ventilation (ICC-CPR) in cardiac arrest.
METHODS: PubMed, Web of Science, Embase, MEDLINE (Ovid/LWW) and the Cochrane Libraries were searched up from inception to July 31, 2022. Human and animal studies comparing CCC-CPR versus ICC-CPR were included. Outcome variables were return of spontaneous circulation (ROSC), time to ROSC, survival to discharge, 1-month survival, survival at 4 h, good neurological function, mean arterial pressure (MAP) and other clinical parameters. Jadad Scale and Newcastle-Ottawa Scale were used to assess the study quality and risk of bias.
RESULTS: The systematic search identified eight studies on humans and twelve studies on animal trials. There were no significant differences in ROSC (odd ratios [OR] 1.07; 95% confidence interval [CI]: 0.86-1.32; P = 0.55), survival to hospital discharge (OR 1.04; 95%CI 0.77-1.42; P = 0.79), 1-month survival (OR 1.07; 95%CI 0.84-1.36; P = 0.57), and good neurological outcome (OR 0.92; 95%CI 0.84-1.01, P = 0.09) between CCC-CPR and ICC-CPR in human studies. In animal trials, CCC-CPR had significantly higher rate of ROSC (OR = 1.81; 95% CI: 0.94-3.49; P = 0.07), survival at 4 h (OR 2.57; 95% CI: 1.16-5.72; P = 0.02) and MAP (mean difference [MD] 0.79, 95% CI: 0.04-1.53; P = 0.04), even though no significant differences in ROSC time, arterial potential of hydrogen (pH) and partial tension of carbon dioxide (PaCO2).
CONCLUSION: CCC-CPR did not show superiority in human outcomes compared with ICC-CPR, but its effect value was significantly increased in animal experiments. We should take the positive outcomes from animals and apply them to human models, and more physiological mechanisms need to be confirmed in CPR patients with different compression-ventilation strategies to improve the prognosis of cardiac arrest.
参考来源
- Sun M, Zhu A, Tang Y, et al. Continuous compression with asynchronous ventilation improves CPR prognosis? A meta-analysis from human and animal studies. Am J Emerg Med. 2022. PMID: 36435007. doi:10.1016/j.ajem.2022.11.003
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。